AA&MDSIF Newsroom
See what is new on the AA&MDSIF site at a glance. This page displays new content from a wide variety of sources as it is added to the site, including: press releases, news articles, research articles, community events, conferences, and more.
Community Event published
Wednesday, May 15, 2013
Come celebrate AA&MDSIF volunteer Tom Manley's cross-country bike ride to raise money and awareness for bone marrow failure disease as he finishes his ride! Tom started his journey in Newport Beach on April 21 and will finish at Salisbury Beach in Salisbury, MA on May 23 . He is riding in honor of his...
Community Event published
Wednesday, May 15, 2013
The 20th Annual Judy Joyce Memorial Golf Tournament will be held on Friday, June 21 at the North Kingstown Golf Course. This event is organized by Judy Joyce's family and friends in her memory.
The cost is $120, which includes 18 holes of golf, a cart, dinner, and a wind shirt. There will be various raffles as...
Research Article published
Tuesday, May 14, 2013
The most frequent and feared complication of paroxysmal nocturnal hemoglobinuria (PNH) is thrombosis. Recent research has demonstrated that the complement and coagulation systems are closely integrated with each influencing the activity of the other to the extent that thrombin itself has recently been shown to...
Research Article published
Tuesday, May 14, 2013
Paroxysmal nocturnal hemoglobinuria (PNH) is a rare, acquired disorder characterized by chronic intravascular hemolysis as the primary clinical manifestation and morbidities that include anemia, thrombosis, renal impairment, pulmonary hypertension, and bone marrow failure. The prevalence of the PNH clone (from <1-...
Research Article published
Tuesday, May 14, 2013
We chose hepcidin and its related factors as evaluating indicators to determine the degrees of iron overload in myelodysplastic syndromes (MDS) patients. A total of 73 patients and 28 healthy volunteers were enrolled in this study. We performed enzyme-linked immunosorbent assay to measure both bone marrow and...
Research Article published
Tuesday, May 14, 2013
In 1976 the French-American-British (FAB) Leukemia Working Group proposed the first definitions of patients with myelodysplastic syndromes (MDS), namely refractory anemia with excess blasts (RAEB) and chronic myelomonocytic leukemia (CMML). Subsequent publications resulted in additional subgroups that had prognostic...
Research Article published
Tuesday, May 14, 2013
ABSTRACT Myelodysplastic syndromes (MDS) are a group of hematopoietic malignancies characterized by ineffective hematopoiesis. Recently, we identified MDS-associated microRNAs (miRNAs) that are down-regulated in MDS. This study examines possible explanations for that observed down-regulation of miRNA expression in MDS...
Research Article published
Tuesday, May 14, 2013
Lower risk MDS are defined as having low or intermediate 1 risk by the IPSS, and are mainly characterized by anemia in most cases. Supportive care, mainly red blood cell transfusions, remains an important component of their treatment, but expose patients to insufficient correction of anemia , alloimmunization, and...
Research Article published
Tuesday, May 14, 2013
The phase III AZA-001 study established that azacitidine significantly improves overall survival compared with conventional care regimens (hazard ratio 0.58 [95% confidence interval 0.43-0.77], P<0.001). This analysis was conducted to investigate the relationship between treatment response and overall survival. AZA...
Research Article published
Tuesday, May 14, 2013
The International Prognostic Scoring System (IPSS) was recently revised (IPSS-R) under the auspices of the MDS Foundation as a collaborative international effort to refine its prognostic power. Our purpose was to externally validate this new risk model using a large single-institution cohort, determine its prognostic...
Resources For
Online Learning Center
Action Center
Find out how you can further research and treatment. Act now!
This site complies with the HONcode standard for trustworthy health information: verify here.
